Across anti-PD-1 immune checkpoint inhibitors, there are approved indications for the treatment of breast, colorectal, head and neck, and lung cancers and melanoma, while anti-PD-L1 immune checkpoint inhibitors have been approved for breast and lung cancer treatment13–19 (table 1, online supplemental table 1). This evidence concerns the gene CD274 and melanoma.